|
Dermatological Drugs: World Market 2011-2026
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following advantages:You can have our report today Our new study can benefit everybody interested in the development and sale of treatments for skin disorders. You can see where the industry and market are heading, assessing the opportunities, requirements and challenges there. You can find answers and trends - we aim to save you time and aid your decisions. Order our report now, making sure you don't miss out. Please let us help today. Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6 189 seiten | |||||||||||
| Inhalt der Studie: |
Would you like to know how the industry and market for dermatological drugs will develop? There will be trends to watch from 2010 onwards, with areas of high revenue growth. You can have our new repor.....
Would you like to know how the industry and market for dermatological drugs will develop? There will be trends to watch from 2010 onwards, with areas of high revenue growth. You can have our new report now, staying ahead, saving time and aiding your decisions. There, you will see where the greatest opportunities in treating skin disorders will occur. In particular, our new study examines drug markets for treating: • Dermatitis • Skin infections • Acne • Psoriasis. There are high revenues to be made in this sector from 2010 to 2026. We show how you can benefit from the sector's developments and potential. Dermatological drugs form an important segment of the global pharma market, with sales of over $25bn in 2009. New drugs with improved safety and efficacy can gain significant market shares in the future, our study reveals. Novel and generic drug producers can benefit from that sector this decade, our analyses show and explain. There are opportunities for small-molecule and biologic drugs. We cover the world market, its main segments and revenues in leading regions. The introduction and commercial success of biologics led to an expansion of the skin treatments market and highlighted the commercial rewards on offer in this sector. What new types of agent will enter the market, and can those drugs dominate? Where can you find the best commercial opportunities from 2010 onwards? What are the key drivers and restraints in the sector? We show how you can benefit there, letting you assess dermatological market potential now. Analysis and expert views to aid your work - so you won't be left behind Our new report provides you with revenue forecasts, market share analyses, R&D pipeline developments and expert opinion. That way, you can assess prospects, opportunities and threats in the sector. It is that combination of data that sets us apart. We include 99 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas. Report Highlights Companies Listed Abbott Laboratories Actavis Group Actelion Pharmaceuticals AiCuris Allergan Almirall Altana Pharma Amgen Anacor Pharmaceuticals AndroScience Corp AnGes MG Antigenics Apotex Corp. Apotheca Applied Genetics Inc. Dermatics (AGI Dermatics) aRigen Pharmaceuticals Astellas Pharma Astion Pharma Asubio Pharmaceuticals Aurobindo Pharma Barr Laboratories Barrier Therapeutics Bayer Bayer Schering Pharma Bio3 Research BioCryst Pharmaceuticals BioMAS Biomed Research & Technologies Bioskin Biotest Biovail Corporation Birken Bristol-Myers Squibb Can-Fite BioPharma Celgene Corporation Centocor Ortho Biotech Cipher Pharmaceuticals CollaGenex Pharmaceuticals CombinatoRx Coria Laboratories Cosmo Pharmaceuticals Creabilis Therapeutics Critical Therapeutics Cytotech Labs DAVA Pharmaceuticals DeNova Research Derma Sciences DermaTech Dermik Laboratories Dow Pharmaceutical Sciences Dr. Reddy's Laboratories DUSA Pharmaceuticals E. Fougera & Co. Eisai Co. Eli Lilly and Company Epiphany Biosciences Estee Lauder European Medicines Agency (EMA) European Pharmaceutical Market Research Association (EphMRA) F. Hoffman-La Roche Foamix Food and Drug Administration (US FDA) Forward Pharma Galderma Gene Signal International Genentech Genzyme Corporation GlaxoSmithKline (GSK) Graceway Pharmaceuticals Gruenenthal Immune Control (now Corridor Pharmaceuticals) Immune Technologies & Medicine Impax Laboratories Incyte Corporation Inhibitex INSERM Intendis Isotechnika Pharma Ivax Pharmaceuticals Janssen-Cilag Johnson & Johnson Kaken Pharmaceutical L.A.L Clinica Pesquisa e Desenvolvimento Laboratório Teuto Brasileiro Laboratorios Goulart Leo Pharma Ligand Pharmaceuticals L'Oreal Maruho Co. Matrix Laboratories Meda Pharmaceuticals Medicis Pharmaceutical Corporation Medivir Pharma Merck & Co. Merz Pharmaceuticals Mitos Pharmaceuticals Moberg Derma Morria Biopharmaceuticals Mount Sinai School of Medicine Mycenax Biotech Mylan Pharmaceuticals NanoBio Corporation National Cancer Institute National Institute for Health and Clinical Excellence (NICE) National Institute of Allergy and Infectious Diseases (NIAID) Nestlé Nitric BioTherapeutics Northwestern University Novartis International Nycomed Pharma Nycomed US Onset Therapeutics Oplon-Pure Science Orient Pharma OSI Pharmaceuticals Par Pharmaceutical Peplin Pfizer PhotoCure Pola Pharma Provectus Pharmaceuticals QuatRx Pharmaceuticals Rabin Medical Center Ranbaxy Laboratories Ranbaxy Pharmaceuticals Regeneron Pharmaceuticals Roche Pharmaceuticals Roxane Laboratories Sandoz International Sanofi-Aventis Schering-Plough Senetek Serentis Sheba Medical Center Shenyang Sunshine Pharmaceutical Company (3SBio) Shionogi & Co. SkinMedica Sol-gel Technologies Starpharma Holdings Stiefel Laboratories Summit Corporation Takeda Pharmaceuticals Taro Pharmaceuticals Teva Pharmaceutical Industries The American Academy of Dermatology The Medicines and Healthcare Products Regulatory Agency (MHRA) Topica Pharmaceuticals Tufts Medical Center University of Bradford University of British Columbia University of California, Irvine Valeant Pharmaceuticals Vascular Biogenics (VBL Therapeutics) Vicept Therapeutics Warner Chilcott Watson Laboratories Watson Pharmaceuticals Welichem Biotech Wyeth Pharmaceuticals Zalicus Zurita Laboratorio Farmaceutico [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 Dermatological Market Review 1.2 Aims, Scope and Format of the Report 1.2.1 Scope of the Report 1.2.2 Chapter Outlines 1.3 Research and Analysis Methods 2. Introduction to Dermatological Diseases and Treatments 2.1 An Introduction to Dermatology 2.1.1 The Structure of the Skin 2.1.2 Hair 2.1.3 Nails 2.1.4 Sweat and Sebaceous Glands 2.2 Functions of the Skin 2.2.1 Protection 2.2.2 Sensation 2.2.3 Vitamin D Synthesis 2.2.4 Temperature Regulation and Heat Insulation 2.2.5 Storage 2.2.6 Prevention of Water Loss 2.3 Common Skin Diseases 2.4 An Introduction to Acne Vulgaris 2.4.1 Acne Conglobata 2.4.2 Acne Fulminans 2.4.3 Gram-Negative Folliculitis 2.4.4 Pyoderma Faciale 2.4.5 Causes of Acne 2.5 An Introduction to Dermatitis 2.5.1 Atopic Dermatitis 2.5.2 Contact Dermatitis 2.5.3 Seborrheic Dermatitis 2.5.4 Nummular Dermatitis 2.5.5 Perioral Dermatitis 2.6 An Introduction to Psoriasis 2.6.1 Plaque Psoriasis 2.6.2 Guttate Psoriasis 2.6.3 Pustular Psoriasis 2.6.4 Inverse Psoriasis 2.6.5 Erythrodermic Psoriasis 2.7 An Introduction to Rosacea 2.7.1 Erythematotelangiectatic Rosacea 2.7.2 Papulopustular Rosacea 2.7.3 Phymatous Rosacea 2.7.4 Ocular Rosacea 2.8 An Introduction to Alopecia 2.8.1 Alopecia Areata 2.8.2 Alopecia Totalis 2.8.3 Alopecia Universalis 2.8.4 Androgenetic Alopecia 2.8.5 Alopecia Barbae 2.8.6 Alopecia Mucinosa 2.8.7 Traction Alopecia 2.8.8 Anagen Effluvium 2.8.9 Telogen Effluvium 2.9 An Introduction to Infectious Diseases of the Skin 2.9.1 Bacterial Skin Infections 2.9.1.1 Impetigo 2.9.1.2 Folliculitis 2.9.1.3 Cellulitis 2.9.1.4 Furunculosis 2.9.1.5 Carbuncle 2.9.2 Fungal Skin Infections 2.9.2.1 Tinea Pedis (Athlete's Foot) 2.9.2.2 Tinea Unguium (Ringworm of the Nails) 2.9.2.3 Tinea Corporis (Ringworm of the Skin) 2.9.2.4 Tinea Capitis (Scalp Ringworm) 2.9.2.5 Kerions 2.9.3 Viral Skin Infections 2.9.3.1 Molluscum Contagiosum 2.9.3.2 Warts 2.9.3.3 Herpes Simplex 2.9.3.4 Chickenpox 2.9.3.5 Herpes Zoster 2.10 Common Skin Treatments 2.10.1 Creams and Semisolid Emulsions 2.10.2 Ointments 2.10.3 Lotions 2.10.4 Solutions 2.10.5 Occlusive Therapy 2.10.6 Cleansing Agents 2.10.7 Protecting Powders and Hydrophilic Polymer 2.10.8 Anti-Infective Agents 2.10.9 Anti-Inflammatory Agents 3. The World Dermatological Drugs Market, 2009-2026 3.1 The World Dermatological Drugs Market in 2009 3.2 The Infectious Skin Diseases Drug Market Dominates the World Dermatological Market 3.3 Valtrex was the Leading Drug in the Dermatological Market in 2009 3.4 GlaxoSmithKline (GSK) Became the Leader in the Dermatological Market After the Stiefel Acquisition 3.4.1 Changing Landscape of the Dermatological Treatments Market 3.5 The World Dermatological Market Forecast, 2010-2026 3.5.1 Changing Market Shares of the Leading Segments 3.5.2 The Psoriasis Market Will Show the Highest Increase in Market Share 3.6 The Future of the Dermatological Treatments Market 3.6.1 Dermatological Blockbuster Drugs Will Be Fewer in Future 4. The World Infectious Skin Diseases Drug Market, 2009-2026 4.1 The World Infectious Skin Diseases Drugs Market in 2009 4.1.1 Viral Infection Products Led the Dermatological Anti-Infectives Market in 2009 4.1.2 In 2009, Systemic Antiviral Products Accounted for the Highest Share of the Market 4.2 The World Infectious Skin Disease Market Forecast, 2010-2026 4.3 Valtrex (Valacyclovir) 4.3.1 Valtrex Led the Skin Infectious Diseases Market in 2009 4.3.2 Declining Branded Sales and Revenues as Generics Reach Market 4.4 Aldara (Imiquimod) 4.4.1 Aldara was the Leading Topical Antiviral Drug in 2009 4.4.2 Graceway Pharmaceuticals Failed to Block the Launch of Generics 4.4.3 Aldara Sales Will Decline Sharply Owing to the Launch of Generics 4.5 Zovirax (Acyclovir) 4.5.1 Market Launch and Status 4.5.2 Analysis of Forecast Zovirax Sales 2009-2026 4.6 Bactroban (Mupirocin) 4.6.1 Sales Forecast for Bactroban, 2009-2026 4.7 Lamisil (Terbinafine) 4.7.1 Lamisil was the Leading Dermatological Antifungal Treatment in 2009 4.8 The World Infectious Skin Diseases Market - Summary 5. The World Dermatitis Drug Market, 2009-2026 5.1 The World Dermatitis Market in 2009 5.1.1 Topical Corticosteroids Led the Dermatitis Market in 2009 5.2 World Dermatitis Market Analysis 2010-2026 5.2.1 Unmet Needs in the Dermatitis Treatments Market 5.3 Protopic (Tacrolimus) 5.3.1 Protopic Sales to Benefit from Expanded Indication 5.3.2 Protopic Will Show an Early Increase in Sales - But Will It Last? 5.4 Elocon (Mometasone Furoate) 5.4.1 Elocon Suffers From Generic Competition 5.5 Elidel (Pimecrolimus) 5.5.1 Decline in Sales Due to the Black Box Warnings 5.5.2 Further Clinical Development of Elidel to Stimulate Sales Growth? 5.6 Clob X/ Clobex (Clobetasol Propionate) 5.6.1 Current and Forecasted Sales for Clobex 5.7 The World Dermatitis Market - Summary 6. The World Acne Drug Market, 2009-2026 6.1 The World Acne Market in 2009 6.1.1 Available Treatment and Unmet Medical Needs 6.1.2 Products Leading the Acne Market, 2009 6.2 World Acne Market Forecast, 2010-2026 6.3 Solodyn (Minocycline) 6.3.1 Solodyn Currently Leads the World Acne Market 6.3.2 Will Solodyn Sales Continue to Grow? 6.4 Claravis (Isotretinoin) 6.4.1 Removal of Accutane from Market: Domination by Generics 6.4.2 Claravis Sales Forecast Analysis, 2009-2026 6.5 Differin (Adapalene) 6.5.1 Sales Forecast for Differin, 2009-2026 6.5.2 Differin - Life Cycle Management 6.6 Diane (Cyproterone and Ethinylestradiol) 6.6.1 Sales Forecast for Diane, 2009-2026 6.7 Doryx (Doxycycline Hyclate) 6.7.1 Increasing Prescriptions for Doryx 150mg 6.7.2 Sales Forecast for Doryx, 2010-2026 6.8 Combination Products: The Future Topical Acne Treatments of Choice? 6.8.1 Epiduo (Adapaline and Benzoyl Peroxide) 6.8.1.1 Superior Clinical Efficacy Will Drive Market Sales 6.8.1.2 Epiduo - Fastest Growing Product in Dermatology, 2009 6.8.2 Ziana (Clindamycin and Tretinoin) 6.8.2.1 Clinical Efficacy of Combination Better Than Those of Individual Components 6.8.2.2 Market Performance of Ziana, 2009 6.8.2.3 Stiefel's Veltin - Competitor of Ziana - Receives FDA Approval 6.9 The World Acne Market - Summary 7. The World Psoriasis Drug Market, 2009-2026 7.1 The World Psoriasis Market in 2009 7.1.1 Leading Drugs in the Psoriasis Market 7.1.2 Biologic Treatments Led the Psoriasis Market in 2009 7.2 World Psoriasis Market Forecast, 2010-2026 7.3 Enbrel (Etanercept) 7.3.1 Enbrel Led the Psoriasis Market in 2009 7.3.2 Losing Market Leadership: Prominent Factors 7.3.2.1 Losing Market Share to Humira 7.3.2.2 Losing Market Share to Stelara 7.3.2.3 Entry of Biosimilars 7.3.2.4 Competition from Pipeline Products 7.4 Humira (Adalimumab) 7.4.1 Gaining Market Acceptance to Become the Leader in the Psoriasis Market 7.5 Stelara (Ustekinumab) 7.5.1 Stelara Achieving the Highest Sales Growth in the Psoriasis Market 7.6 Topical Treatment: The Mainstay for Mild Psoriasis 7.7 Daivobet (Calcipotriol & Betamethasone) 7.7.1 Daivobet Led the Topical Psoriasis Market in 2009 7.7.2 Lifecycle Management for its Leading Psoriasis Drug 7.7.3 Daivobet Will Benefit from the Removal of Raptiva from the Market 7.7.4 Will Sales of Daivobet Continue to Grow? 7.8 Taclonex (Calcipotriol & Betamethasone) 7.8.1 Sales Forecast for Taclonex, 2010-2026 7.9 Dovonex (Calcipotriol) 7.9.1 Generic Competition 7.9.2 Analysis of Dovonex Sales Forecast, 2009-2026 7.10 The World Psoriasis Market - Summary 8. The World Market for Miscellaneous Dermatological Drugs, 2009-2026 8.1 The Miscellaneous Dermatological Drug Market in 2009 8.2 The Miscellaneous Dermatological Drug Market Analysis, 2010-2026 8.3 Propecia (Finasteride 1mg) 8.3.1 Sales of Propecia Will Fall, 2009-2026 8.3.2 Propecia Faces Competition from Other Alopecia Products 8.4 Surgicel 8.4.1 Forecast Sales of Surgicel, 2009-2026 8.5 The Miscellaneous Market - Summary 9. The Dermatological Pharmaceutical R&D Pipeline 9.1 The Potential of the Dermatological Market has Encouraged R&D 9.2 New Technology in R&D Pipeline Developments 9.2.1 Reformulation 9.2.2 Combination Treatments 9.2.3 New Mechanisms 9.2.4 Drug Delivery Technology 9.3 Potential Entrants 9.4 Pipeline Products in the Dermatitis Sector 9.4.1 MRX6, Morria Biopharmaceuticals 9.4.2 Elidel (Pimecrolimus), Novartis 9.5 Pipeline Products in the Infectious Skin Disease Sector 9.5.1 NB-001, NanoBio Corporation 9.6 Pipeline Products in the Acne Sector 9.6.1 Visonac, PhotoCure 9.6.2 ACAT Inhibitor, Graceway Pharmaceuticals 9.7 Pipeline Products in the Psoriasis Sector 9.7.1 Briakinumab, Abbott Laboratories 9.7.2 Apremilast, Celgene Corporation 9.7.3 AN2728, Anacor Pharmaceuticals 9.8 Pipeline Products for Miscellaneous Dermatological Applications 9.8.1 PEP005, Leo Pharma 9.9 Innovation Rules for Early-Stage Pipeline Drugs 10. Dermatological Drugs: Leading National Markets, 2009-2026 10.1 Countries Leading the World Dermatological Market in 2009 10.2 The Nine Leading National Markets for Dermatological Drugs 10.2.1 The Dermatological Market in the US, 2009-2026 10.2.2 The Dermatological Market in Japan, 2009-2026 10.2.3 The Dermatological Market in Germany, 2009-2026 10.2.4 The Dermatological Market in France, 2009-2026 10.2.5 The Dermatological Market in the UK, 2009-2026 10.2.6 The Dermatological Market in Italy, 2009-2026 10.2.7 The Dermatological Market in Spain, 2009-2026 10.2.8 The Dermatological Market in India, 2009-2026 10.2.9 The Dermatological Market in China, 2009-2026 11. Issues Affecting the World Dermatological Drugs Market 11.1 SWOT Analysis of the World Dermatological Market 11.2 Market Drivers 11.3 Market Restraints 11.4 There is Scope for Expansion into Related Markets 11.5 Advances in Technology are Likely to Bring Benefits to the Market 11.6 Consumer Bargaining Power 11.7 Competition in the Dermatological Market Will Become Increasingly Intense 11.8 Substitutes 11.9 Generic Drugs in This Market - How Significant is Their Threat? 12. Expert Opinions 12.1 Interview with the Product Development Director of a Pharmaceutical Company 12.1.1 The Future of the Dermatological Treatments Market 12.1.2 Areas Offering Growth Opportunities 12.1.3 Future Development Trends 12.1.4 Pipeline Products 12.1.5 Unmet Needs for Dermatological Treatments 12.1.6 Threats Facing the Dermatological Treatments Market 12.2 Interview with Dr M.J. Thornton, Cutaneous Biology Group, University of Bradford, UK 12.2.1 Androgen-Based Science and Dermatology 12.2.2 Principal Areas for Dermatological Research 12.2.3 Unmet Needs in the Dermatological Drugs Market 12.2.4 Pipeline Products and Technologies 12.2.5 Challenges Facing the Dermatological Drugs Market 13. Conclusions 13.1 The World Dermatological Market Will Experience Gradual Sales Growth 13.2 Will The Skin Infections Market Continue to Dominate the Market? 13.3 Dermatological Market Landscape: Companies Active in this Market 13.4 Need for Novel Therapies for the Treatment of Dermatitis 13.5 Combination Treatments and Lifecycle Management in the Acne Market 13.6 Biologics Will Drive Growth in the Psoriasis Market 13.7 Why Growth of the Overall World Dermatological Market Will Continu [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 3.1 The World Dermatological Drugs Market by Leading Segments ($m), 2009 Table 3.2 Leading Drugs in the World Dermatological Drugs Market ($m), 2009 Table 3.3 Leading Companies in the Dermatological Drugs Market ($m), 2009 Table 3.4 World Dermatological Drugs Market Forecast ($m), 2009-2018 Table 3.5 World Dermatological Drugs Market Forecast ($m), 2019-2026 Table 3.6 Market Shares (%) of Leading Segments in the Dermatological Drugs Market, 2009, 2015, 2020 & 2026 Table 4.1 Infectious Skin Diseases Drugs Market by Leading Products ($m), 2009 Table 4.2 Infectious Skin Diseases Drugs Market ($m) by Class, 2009 Table 4.3 World Infectious Skin Diseases Drugs Market Forecast ($m), 2009-2018 Table 4.4 World Infectious Skin Diseases Drugs Market Forecast ($m), 2019-2026 Table 4.5 Market Shares (%) of the Leading Skin Infection Drugs, 2009, 2015, 2020 & 2026 Table 5.1 Dermatitis Drugs Market ($m) by Leading Products, 2009 Table 5.2 Dermatitis Drugs Market ($m) by Class, 2009 Table 5.3 World Dermatitis Drugs Market Forecast ($m), 2009-2018 Table 5.4 World Dermatitis Drugs Market Forecast ($m), 2019-2026 Table 5.5 Market Shares (%) of the Leading Dermatitis Drugs, 2009, 2015, 2020 & 2026 Table 6.1 Acne Drugs Market ($m) by Class, 2009 Table 6.2 Acne Drugs Market ($m) by Leading Products, 2009 Table 6.3 World Acne Drugs Market Forecast ($m), 2009-2018 Table 6.4 World Acne Drugs Market Forecast ($m), 2019-2026 Table 6.5 Market Shares (%) of the Leading Acne Drugs, 2009, 2015, 2020 & 2026 Table 7.1 Psoriasis Drugs Market ($m) by Leading Products, 2009 Table 7.2 Psoriasis Drugs Market ($m) by Class, 2009 Table 7.3 World Psoriasis Drugs Market Forecast ($m), 2009-2018 Table 7.4 World Psoriasis Drugs Market Forecast ($m), 2019-2026 Table 7.5 Market Shares (%) of the Leading Psoriasis Drugs, 2009, 2015, 2020 & 2026 Table 8.1 Leading Products in the Miscellaneous Dermatological Drugs Market ($m), 2009 Table 8.2 Forecast for Miscellaneous Dermatological Drugs Market ($m), 2009-2018 Table 8.3 Forecast for Miscellaneous Dermatological Drugs Market ($m), 2019-2026 Table 9.1 Key Pipeline Products for the Treatment of Dermatitis, 2010 Table 9.2 Key Pipeline Products for the Treatment of Infectious Skin Diseases, 2010 Table 9.3 Key Pipeline Products for the Treatment of Acne, 2010 Table 9.4 Key Pipeline Products for the Treatment of Psoriasis, 2010 Table 9.5 Key Pipeline Agents: Miscellaneous Dermatological Treatments, 2010 Table 10.1 Countries Leading the World Dermatological Drug Market ($m), 2009 Table 10.2 Dermatological Market Forecasts ($m) for the Nine Leading National Markets, 2009-2018 Table 10.3 Dermatological Market Forecasts ($m) for the Nine Leading National Markets, 2019-2026 Table 10.4 Market Shares (%) of the Nine Leading National Markets, 2009, 2015, 2020 & 2026 Table 11.1 SWOT Analysis of the World Dermatological Drug Market, 2010 Figure 3.1 Dermatological Drugs Market Shares (%) by Leading Segments, 2009 Figure 3.2 Sales ($m) of Leading Drugs in the World Dermatological Drugs Market, 2009 Figure 3.3 Market Shares (%) of the Leading Companies in the Dermatological Drugs Market, 2009 Figure 3.4 World Dermatological Drugs Market Forecast ($m), 2009-2026 Figure 3.5 Forecasts ($m) for Leading Segments of the Dermatological Drugs World Market, 2009-2026 Figure 4.1 Infectious Skin Disease Drugs: World Market ($m), 2009-2026 Figure 4.2 Leading Infectious Skin Disease Drugs: Sales ($m), 2009-2026 Figure 4.3 Valtrex Sales Forecast ($m), 2009-2026 Figure 4.4 Aldara Sales Forecast ($m), 2009-2026 Figure 4.5 Zovirax Sales Forecast ($m), 2009-2026 Figure 4.6 Bactroban Sales Forecast ($m), 2009-2026 Figure 4.7 Lamisil Sales Forecast ($m), 2009-2026 Figure 4.8 Market Shares (%) of Leading Skin Infection Drugs, 2009 Figure 4.9 Market Shares (%) of Leading Skin Infection Drugs, 2015 Figure 4.10 Market Shares (%) of Leading Skin Infection Drugs, 2020 Figure 4.11 Market Shares (%) of Leading Skin Infection Drugs, 2026 Figure 5.1 Dermatitis Drugs: World Market ($m), 2009-2026 Figure 5.2 Leading Dermatitis Drugs: Sales ($m), 2009-2026 Figure 5.3 Protopic Sales Forecast ($m), 2009-2026 Figure 5.4 Elocon Sales Forecast ($m), 2009-2026 Figure 5.5 Elidel Sales Forecast ($m), 2009-2026 Figure 5.6 Clob X/Clobex Sales Forecast ($m), 2009-2026 Figure 5.7 Market Shares (%) of Leading Dermatitis Drugs, 2009 Figure 5.8 Market Shares (%) of Leading Dermatitis Drugs, 2015 Figure 5.9 Market Shares (%) of Leading Dermatitis Drugs, 2020 Figure 5.10 Market Shares (%) of Leading Dermatitis Drugs, 2026 Figure 6.1 Acne Drugs: World Market ($m), 2009-2026 Figure 6.2 Leading Acne Drugs: Sales ($m), 2009-2026 Figure 6.3 Solodyn Sales Forecast ($m), 2009-2026 Figure 6.4 Claravis Sales Forecast ($m), 2009-2026 Figure 6.5 Differin Sales Forecast ($m), 2009-2026 Figure 6.6 Diane Sales Forecast ($m), 2009-2026 Figure 6.7 Doryx Sales Forecast ($m), 2009-2026 Figure 6.8 Market Shares (%) of Leading Acne Drugs, 2009 Figure 6.9 Market Shares (%) of Leading Acne Drugs, 2015 Figure 6.10 Market Shares (%) of Leading Acne Drugs, 2020 Figure 6.11 Market Shares (%) of Leading Acne Drugs, 2026 Figure 7.1 Psoriasis Drugs: World Market ($m), 2009-2026 Figure 7.2 Leading Psoriasis Drugs: Sales ($m), 2009-2026 Figure 7.3 Enbrel Sales Forecast ($m), 2009-2026 Figure 7.4 Humira Sales Forecast ($m), 2009-2026 Figure 7.5 Stelara Sales Forecast ($m), 2009-2026 Figure 7.6 Daivobet Sales Forecast ($m), 2009-2026 Figure 7.7 Taclonex Sales Forecast ($m), 2009-2026 Figure 7.8 Dovonex Sales Forecast ($m), 2009-2026 Figure 7.9 Market Shares (%) of Leading Psoriasis Drugs, 2009 Figure 7.10 Market Shares (%) of Leading Psoriasis Drugs, 2015 Figure 7.11 Market Shares (%) of Leading Psoriasis Drugs, 2020 Figure 7.12 Market Shares (%) of Leading Psoriasis Drugs, 2026 Figure 8.1 Forecast for Miscellaneous Dermatological Drugs Market ($m), 2009-2026 Figure 8.2 Sales Forecast for Leading Drugs in the Miscellaneous Dermatological Market ($m), 2009-2026 Figure 8.3 Propecia Sales Forecast ($m), 2009-2026 Figure 8.4 Surgicel Sales Forecast ($m), 2009-2026 Figure 10.1 Sales ($m) for the Leading Countries in the Dermatological Market, 2009 Figure 10.2 US and Japan: Dermatological Market Forecasts ($m), 2009-2026 Figure 10.3 European, Indian and Chinese Dermatological Market Forecasts ($m), 2009-2026 Figure 10.4 Dermatological Market Shares (%) by Country, 2009 Figure 10.5 Dermatological Market Shares (%) by Country, 2015 Figure 10.6 Dermatological Market Shares (%) by Country, 2020 Figure 10.7 Dermatological Market Shares (%) by Country, 2026 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
